Literature DB >> 10695633

Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C.

F Ramalho1, A Costa, A Pires, P Cabrita, F Serejo, A P Correia, N Fatela, H Clória, J Lopes, H C Pinto, R Marinho, M Raimundo, J Velosa, A Batista, M C de Moura.   

Abstract

Our objective was to evaluate the histopathological features of chronic hepatitis C of 64 liver biopsies and to correlate this with the route of transmission of hepatitis C virus, the genotype of HCV, and the patient's age. Moderate chronic hepatitis was the most frequently observed (62.5%). Cirrhosis was observed in 14 patients (21.9%) and was more frequently found among patients over 40 years of age (34.3% vs. 6.9%, P = 0.025). The mean histopathological activity index (HAI) was significantly higher in the sporadic (10+/-3.1) than the posttransfusional (7.5+/-3.7) and the intravenous drug use (IVDU) groups (6.3+/-2.8) (P<0.02). Moreover the sporadic group showed more fibrosis (P<0.04) than the posttransfusional group. No liver cirrhosis was found in the IVDU group. The overall prevalence of HCV variants was: 54.7% type 1b, 4.6% type 1a, 37.5% type 2c, 1.6% type 2b, 1.6% type 2. The genotype distribution showed no relation to the HAI, hepatitis activity (grade), and fibrosis (stage) of the liver disease. In conclusion, the sporadic route of transmission of HCV was related to a more severe chronic hepatic disease, a finding that could influence future antiviral therapies. The predominance of HCV type 1b in this study reflects the higher frequency of this variant in our area. Our data suggests that the ultimate consequence of HCV chronic infection depends on patient age rather than on HCV genotype.

Entities:  

Mesh:

Year:  2000        PMID: 10695633     DOI: 10.1023/a:1005442317680

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

Authors:  E Silini; R Bottelli; M Asti; S Bruno; M E Candusso; S Brambilla; F Bono; G Iamoni; C Tinelli; M U Mondelli; G Ideo
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

2.  The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C.

Authors:  D R Nelson; C G Marousis; G L Davis; C M Rice; J Wong; M Houghton; J Y Lau
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

3.  Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type I and type II.

Authors:  D Qu; J S Li; L Vitvitski; S Mechai; F Berby; S P Tong; F Bailly; Q S Wang; J L Martin; C Trépo
Journal:  J Hepatol       Date:  1994-07       Impact factor: 25.083

4.  Comparative histology of acute hepatitis B and non-A, non-B in Leuven and Padova.

Authors:  M Rugge; M J Vanstapel; V Ninfo; G Realdi; F Tremolada; P G Montanari; B van Damme; J Fevery; J de Groote; V Desmet
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

5.  The natural history of hepatitis C: clinical experiences.

Authors:  R Müller
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

6.  Hepatitis C virus genotypes are not responsible for development of serious liver disease.

Authors:  M Yamada; S Kakumu; K Yoshioka; Y Higashi; K Tanaka; T Ishikawa; M Takayanagi
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

7.  Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.

Authors:  M Honda; S Kaneko; A Sakai; M Unoura; S Murakami; K Kobayashi
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

8.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

9.  Genotypic analysis of hepatitis C virus in American patients.

Authors:  K Mahaney; V Tedeschi; G Maertens; A M Di Bisceglie; J Vergalla; J H Hoofnagle; R Sallie
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

10.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  J H Lefkowitch; E R Schiff; G L Davis; R P Perrillo; K Lindsay; H C Bodenheimer; L A Balart; T J Ortego; J Payne; J L Dienstag
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

View more
  6 in total

Review 1.  Viral hepatitis: new data on hepatitis C infection.

Authors:  Erzsébet Szabó; Gábor Lotz; Csilla Páska; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

2.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

3.  Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.

Authors:  Rachel Abraham; Banumathi Ramakrishna; Avinash Balekuduru; Hubert Darius J Daniel; Priya Abraham; C Eapen Eapen; George Kurian
Journal:  Indian J Gastroenterol       Date:  2009-08-21

Review 4.  The epidemiology of hepatitis C infection in the United States.

Authors:  Vinod K Rustgi
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

5.  A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI).

Authors:  Waqar Ahmad; Bushra Ijaz; Fouzia T Javed; Sana Gull; Humaira Kausar; Muhammad T Sarwar; Sultan Asad; Imran Shahid; Aleena Sumrin; Saba Khaliq; Shah Jahan; Asim Pervaiz; Sajida Hassan
Journal:  BMC Gastroenterol       Date:  2011-04-21       Impact factor: 3.067

6.  Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.

Authors:  Claudia Palladino; Ifeanyi Jude Ezeonwumelu; Rute Marcelino; Verónica Briz; Inês Moranguinho; Fátima Serejo; José Fernando Velosa; Rui Tato Marinho; Pedro Borrego; Nuno Taveira
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.